Finance

Lists
CNTB:NASDAQ
Connect Biopharma Holdings Ltd
$1.28
-0.78%
(-0.0100) 1D
$1.29
+0.78% (+0.0100)
After hours
Closed: Sep 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNTB...
Open
$1.25
High
$1.32
Low
$1.25
Mkt. cap
80.61M
Avg. vol.
1.42M
Volume
1.28M
52-wk high
$3.82
52-wk low
$1.06
EPS
-$1.20
Beta
-0.23
Shares outstanding
62.97M
No. of employees
64
Open
$1.25
High
$1.32
Low
$1.25
Mkt. cap
80.61M
Avg. vol.
1.42M
Volume
1.28M
52-wk high
$3.82
52-wk low
$1.06
EPS
-$1.20
Beta
-0.23
Shares outstanding
62.97M
No. of employees
64
News stories
From web sources and news partners
About Connect Biopharma Holdings Ltd
CEO-
Employees64
Founded2012
Headquarters-
SectorBiotechnology
Websiteconnectbiopharm.com
Analyst ratings
Based on 7 analysts giving stock ratings to CNTB in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CNTB in the last 3 months.
Highest
Current $1.28
$10.00 (+681.25%)
Average
$7.29 (+469.53%)
Lowest
$4.00 (+212.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$7.00
+446.9%
09/17/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$4.00
+212.5%
09/17/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$6.00
+368.7%
09/16/2026
Thomas Flaten
Lake Street
Buy
Maintained
$9.00
+603.1%
09/15/2026
Julian Harrison
BTIG
Buy
Maintained
$10.00
+681.2%
08/27/2026
Biren Amin
Piper Sandler
Buy
Maintained
$7.00
+446.9%
08/13/2026
Mazahir Alimohamed
Oppenheimer
Buy
Initiated
$8.00
+525%
07/09/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Initiated
$4.00
+212.5%
05/21/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$7.50
+485.9%
04/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
16.00K
-
169.00K
2.77M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11.11M
11.28M
15.03M
16.27M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.58M
4.24M
4.75M
4.10M
Operating expense
17.69M
15.53M
19.78M
20.37M
Total operating expenses
17.69M
15.53M
19.78M
20.37M
Operating income
-17.68M
-15.53M
-19.61M
-17.60M
Other non operating income
-7.00K
60.00K
-3.00K
67.00K
EBT including unusual items
-17.14M
-15.08M
-19.35M
-17.22M
EBT excluding unusual items
-17.14M
-15.08M
-19.35M
-17.22M
Income tax expense
61.00K
27.00K
48.00K
60.00K
Effective tax rate
-0.36%
-0.18%
-0.25%
-0.35%
Other operating expenses
-
-
-
-
Net income
-17.20M
-15.11M
-19.40M
-17.28M
Net profit margin
-107,500.00%
-
-11,478.11%
-624.42%
Earnings per share
-0.31
-0.27
-0.34
-0.27
Interest and investment income
545.00K
384.00K
260.00K
313.00K
Interest expense
-
-
-
-
Net interest expenses
545.00K
384.00K
260.00K
313.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.50M
-15.34M
-19.44M
-17.44M
Gain or loss from assets sale
-
3.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps